Related Experiment Video

Updated: Aug 14, 2026

The Examination of Peroxidase-Positive Leukocytes in Semen
04:36

The Examination of Peroxidase-Positive Leukocytes in Semen

Published on: January 19, 2024

Myeloperoxidase genetic polymorphisms modulate human neutrophil enzyme activity: genetic determinants for

Isabelle Chevrier1, David-Alexandre Tregouet, Simone Massonnet-Castel

  • 1Université Paris-Descartes, Faculté de Médecine, INSERM UMRS 490, 45 rue des Saints-Pères, 75270 Paris Cedex 06, France.

Atherosclerosis
|November 18, 2005
PubMed
Abstract

Insights

Genetic variations in the myeloperoxidase (MPO) gene, specifically the -638C > A and V53F polymorphisms, are linked to increased MPO activity. These findings suggest a potential role in cardiovascular disease risk.

Area of Science:

  • Biochemistry
  • Genetics
  • Cardiovascular Research

Background:

  • Myeloperoxidase (MPO) is a leukocyte hemoprotein implicated in atherosclerosis and cardiovascular disease.
  • Previous research identified novel genetic polymorphisms within the MPO gene.

Purpose of the Study:

  • To investigate the impact of MPO gene polymorphisms on human neutrophil MPO activity.
  • To utilize haplotype analysis for a comprehensive evaluation of genetic influences on MPO activity.

Main Methods:

  • Isolated neutrophils from 102 blood donors for MPO activity measurement.
  • Genotyped subjects for MPO gene polymorphisms in both 5' non-coding and coding regions.
  • Performed single-point and haplotype analyses to assess genotype-phenotype correlations.

Main Results:

  • The -638C > A and V53F polymorphisms showed a significant association with MPO activity.
  • Haplotype analysis confirmed that haplotypes carrying the -638A or 53F alleles increased MPO activity.

Conclusions:

  • The -638C > A and V53F MPO gene polymorphisms are associated with elevated enzymatic activity.
  • These polymorphisms may serve as genetic determinants for cardiovascular disease risk, given MPO's suspected role as a biomarker.

More Related Videos

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples05:17

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples

Published on: July 28, 2016

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...